Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
for Endometrial Cancer
1 location in Bethesda
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18 - 120
Code: NCT06253494·Phase 1, Phase 2·Recruiting·Listed Feb 2024